Ticker

Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has been given an average recommendation of "Hold" by the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2025. “In 2025, we strengthened Rocket's leadership in cardiovascular gene therapy,…

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference and Leerink Partners Global Healthcare Conference in Boston and Miami, respectively. Gaurav…

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) have received a consensus rating of "Hold" from the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and eight have issued a buy recommendation